Pillar Biosciences, LC-SCRUM-Asia and LSI Medience have formed a liquid-biopsy collaboration that is expected to screen approximately 2,000 lung cancer patients over two years in Japan, using circulating cell-free DNA and RNA to identify genomic alterations relevant to biomarker-driven clinical research. Pillar’s oncoReveal Essential+ assay has been validated at LSI Medience for the programme, and testing is planned to begin following approval of a revised LC-SCRUM-Asia protocol. LSI Medience will perform the blood-based testing rather than shipping every specimen to Pillar, creating a decentralized laboratory model inside one of Asia’s major precision-oncology research networks.
The scale is important because lung cancer increasingly requires molecular classification before treatment decisions can be made. Actionable alterations involving EGFR, ALK, ROS1, RET, MET, BRAF, KRAS and other drivers can change which targeted therapy or clinical study is appropriate, yet tissue biopsies may provide insufficient material, become difficult to repeat or fail to capture evolving metastatic disease. Liquid biopsy offers another route by recovering tumor-derived nucleic acids released into the bloodstream.
Why is LC-SCRUM-Asia interested in both cfDNA and cfRNA?
Most commercial liquid-biopsy discussions focus on circulating tumor DNA because mutations, insertions and deletions can often be detected from DNA fragments in plasma. Some important lung cancer alterations, however, involve gene fusions or transcript-level events that can be challenging to detect optimally from fragmented DNA alone.
RNA analysis can complement DNA because fusion transcripts directly reflect the rearranged gene product being expressed. Combining cfDNA and cfRNA therefore creates the potential to recover different classes of clinically relevant alterations from one blood-based workflow.
LC-SCRUM-Asia says the combination is intended to support broad genomic screening and improve identification of patients who may qualify for biomarker-driven studies and emerging precision therapies. Pillar emphasizes rapid targeted next-generation sequencing rather than whole-genome discovery as the core workflow.
Why can tissue testing become difficult in lung cancer?
Many patients with advanced lung cancer are diagnosed using small core biopsies, needle aspirates or bronchoscopic samples rather than large surgical specimens. Pathologists must first establish the diagnosis and may need immunohistochemistry and PD-L1 testing before molecular analysis is considered, creating competition for a limited amount of tissue.
Repeat biopsy can also be difficult. A metastatic lesion may be located close to major blood vessels, inside bone or another site where obtaining additional tissue carries procedural risk.
Blood collection is comparatively simple and can be repeated during disease progression. That makes liquid biopsy particularly useful when tissue is insufficient or when clinicians want to characterize emerging resistance after targeted treatment.
Does a negative liquid biopsy mean the tumor has no actionable mutation?
No. Tumors differ dramatically in how much DNA or RNA they release into the circulation. Disease volume, anatomical location, vascularity and treatment status can all affect the amount of tumor-derived material present in plasma.
A negative blood test can therefore mean that no relevant alteration was detected in the sampled circulating nucleic acid, not that the cancer is definitively mutation negative. Tissue testing can remain important when liquid biopsy fails to identify a driver in a clinical setting where actionable alterations are still plausible.
This is one reason large prospective screening networks are valuable. They can show not only how often a test detects particular alterations but how the assay performs across histologies, stages, sample qualities and real clinical workflows.
Why does local validation at LSI Medience matter?
Precision diagnostics are increasingly being commercialized through distributed laboratory networks rather than one central global facility. That creates faster turnaround and more practical sample logistics, but it requires the assay to perform reproducibly after transfer to another laboratory.
Validation at LSI Medience establishes that the Japanese laboratory can execute Pillar’s workflow according to the analytical requirements of the project. Testing approximately 2,000 patients then becomes an opportunity to evaluate performance at operational scale rather than only across a limited technical validation set.
For Pillar, this model can also expand reach without building a proprietary testing laboratory in every country. The company supplies NGS technology and workflow while an established local diagnostic provider performs the actual screening.
Why is a research screening network commercially important for a diagnostic company?
Large precision-oncology consortia can help establish the utility of an assay long before routine reimbursement or universal clinical adoption. They generate thousands of real specimens, link molecular results with clinical characteristics and identify whether the assay consistently finds alterations that direct patients into trials.
The same network can expose limitations. If RNA quality is inconsistent, turnaround becomes too slow or results frequently require tissue confirmation, those problems appear at a scale that small validation studies may not reveal.
For pharmaceutical companies, broad molecular screening also increases the pool of patients who can be found for biomarker-selected trials. A rare fusion present in only a small percentage of lung cancers can still support development when a network screens thousands of patients systematically.
What is the bigger significance of the 2,000-patient plan?
Liquid biopsy has already moved well beyond a niche technology, so the novelty here is not simply that blood can reveal a lung cancer mutation. The important development is operational integration: DNA and RNA screening being embedded inside a large regional research network and performed by an established Japanese clinical-testing laboratory.
That structure addresses one of precision medicine’s recurring bottlenecks. A targeted therapy can be extraordinarily effective in the right molecular subgroup and still remain underused if hospitals cannot identify eligible patients quickly enough.
LC-SCRUM-Asia is essentially building the discovery infrastructure around the drugs. Pillar’s commercial opportunity rests on whether oncoReveal Essential+ can help that network find alterations reliably, rapidly and at sufficient scale.
The 2,000-patient programme will consequently provide more than assay volume. It can show whether combined cfDNA and cfRNA analysis adds enough detection and workflow value to become a durable part of lung cancer molecular screening rather than merely an alternative when tissue runs out.
